Inhibition of FAAH Confers Increased Stem Cell Migration Via PPARα
Overview
Affiliations
Regenerative activity in tissues of mesenchymal origin depends on the migratory potential of mesenchymal stem cells (MSCs). The present study focused on inhibitors of the enzyme fatty acid amide hydrolase (FAAH), which catalyzes the degradation of endocannabinoids (anandamide, 2-arachidonoylglycerol) and endocannabinoid-like substances (N-oleoylethanolamine, N-palmitoylethanolamine). Boyden chamber assays, the FAAH inhibitors, URB597 and arachidonoyl serotonin (AA-5HT), were found to increase the migration of human adipose-derived MSCs. LC-MS analyses revealed increased levels of all four aforementioned FAAH substrates in MSCs incubated with either FAAH inhibitor. Following addition to MSCs, all FAAH substrates mimicked the promigratory action of FAAH inhibitors. Promigratory effects of FAAH inhibitors and substrates were causally linked to activation of p42/44 MAPKs, as well as to cytosol-to-nucleus translocation of the transcription factor, PPARα. Whereas PPARα activation by FAAH inhibitors and substrates became reversed upon inhibition of p42/44 MAPK activation, a blockade of PPARα left p42/44 MAPK phosphorylation unaltered. Collectively, these data demonstrate FAAH inhibitors and substrates to cause p42/44 MAPK phosphorylation, which subsequently activates PPARα to confer increased migration of MSCs. This novel pathway may be involved in regenerative effects of endocannabinoids whose degradation could be a target of pharmacological intervention by FAAH inhibitors.
Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases.
Ramer R, Hinz B Cells. 2022; 11(24).
PMID: 36552866 PMC: 9777118. DOI: 10.3390/cells11244102.
Molecular Subtypes Based on the Stemness Index Predict Prognosis in Glioma Patients.
Tan J, Zhu H, Tang G, Liu H, Wanggou S, Cao Y Front Genet. 2021; 12:616507.
PMID: 33732284 PMC: 7957071. DOI: 10.3389/fgene.2021.616507.
Mahurkar-Joshi S, Rankin C, Videlock E, Soroosh A, Verma A, Khandadash A Gastroenterology. 2021; 160(7):2409-2422.e19.
PMID: 33617890 PMC: 8169529. DOI: 10.1053/j.gastro.2021.02.040.
Bublitz K, Bockmann S, Peters K, Hinz B Cells. 2020; 9(10).
PMID: 33076330 PMC: 7602569. DOI: 10.3390/cells9102298.
Luder E, Ramer R, Peters K, Hinz B Oncotarget. 2017; 8(62):105984-105994.
PMID: 29285308 PMC: 5739695. DOI: 10.18632/oncotarget.22517.